SEC FILINGS


Form 10-Q
ACADIA PHARMACEUTICALS INC filed this Form 10-Q on 08/01/2019
Document Outline
Entire Document (3862.5 KB)
Subdocument 1 - 10-Q - 10-Q
Page 1 - UNITED STATES
Page 2 - ACADIA PHARMACEUTICALS INC.
Page 3 - PART I. FINANCIAL INFORMATION
Page 4 - ACADIA PHARMACEUTICALS INC.
Page 5 - ACADIA PHARMACEUTICALS INC.
Page 6 - ACADIA PHARMACEUTICALS INC.
Page 7 - ACADIA PHARMACEUTICALS INC.
Page 8 - ACADIA PHARMACEUTICALS INC.
Page 9 - Commitments and Contingencies,
Page 10 - Chargebacks:
Page 11 - 5. Balance Sheet Details
Page 12 - 7. Fair Value Measurements
Page 13 - 8. Stockholders Equity
Page 14 - Private Equity Financings
Page 15 - Government Investigation
Page 16 - 11. Leases
Page 17 - RESULTS OF OPERATIONS
Page 18 - Financial Operations Overview
Page 19 - Research and Development Expenses
Page 20 - Selling, General and Administrative Expenses
Page 21 - Research and Development Expenses
Page 22 - Selling, General and Administrative Expenses
Page 23 - Off-Balance Sheet Arrangements
Page 24 - Interest Rate Risk
Page 25 - PART II. OTHER INFORMATION
Page 26 - If we do not obtain regulatory approval of NUPLAZID for other indications in the United States, or f
Page 27 - NUPLAZID has only been studied in a limited number of patients and in limited populations. As we con
Page 28 - If we are unable to effectively train and equip our sales force, our ability to successfully commerc
Page 29 - Our ability to generate product revenues will be diminished if NUPLAZID does not receive coverage fr
Page 30 - Healthcare reform measures may negatively impact our ability to sell NUPLAZID or our product candida
Page 31 - We are subject, directly and indirectly, to federal, state and foreign healthcare laws and regulatio
Page 32 - N/A
Page 33 - If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Progr
Page 34 - The FDA granted marketing approval of NUPLAZID for the treatment of hallucinations and delusions ass
Page 35 - If we fail to obtain the capital necessary to fund our operations, we will be unable to successfully
Page 36 - Changes in funding for the FDA and other government agencies could hinder their ability to hire and
Page 37 - Pimavanserin is currently in development for several additional indications other than in PD Psychos
Page 38 - Delays, suspensions and terminations in our clinical trials could result in increased costs to us an
Page 39 - If conflicts arise with our collaborators, they may act in their self-interests, which may be advers
Page 40 - Even if we or our collaborators successfully complete the clinical trials of product candidates, the
Page 41 - If we are unable to attract, retain, and motivate key management, research and development, and sale
Page 42 - If we fail to develop, acquire or in-license other product candidates or products, our business and
Page 43 - We expect that our results of operations will fluctuate, which may make it difficult to predict our
Page 44 - U.S. federal income tax reform could adversely affect our business and financial condition.
Page 45 - We have incurred, and expect to continue to incur, significant costs as a result of laws and regulat
Page 46 - N/A
Page 47 - Confidentiality agreements with employees and others may not adequately prevent disclosure of our tr
Page 48 - The patent applications of pharmaceutical and biotechnology companies involve highly complex legal a
Page 49 - Risks Related to Our Industry
Page 50 - If product liability lawsuits are brought against us, we may incur substantial liabilities and may b
Page 51 - We are dependent on information technology systems, infrastructure and data, which exposes us to dat
Page 52 - If we or our stockholders sell substantial amounts of our common stock, the market price of our comm
Page 53 - If our officers, directors, and largest stockholders choose to act together, they may be able to sig
Page 54 - EXHIBIT
Page 55 - SIGNATURES
Subdocument 2 - EX-31.1 - EX-31.1
Page 1 - N/A
Subdocument 3 - EX-31.2 - EX-31.2
Page 1 - N/A
Subdocument 4 - EX-32.1 - EX-32.1
Page 1 - N/A
Subdocument 5 - EX-32.2 - EX-32.2
Page 1 - N/A
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Item - XML - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Viewer